GvHD results in death in the majority of steroid-resistant patients. This report assesses the safety and efficacy of two regional intra-arterial steroid (IAS) treatment protocols in the largest published cohort of patients with resistant/dependent hepatic and/or gastrointestinal GvHD, as well as identification of predictors of response to IAS and survival. One hundred and twenty patients with hepatic, gastrointestinal GvHD or both were given IAS. Gastrointestinal initial response (IR) and complete response (CR) were documented in 67.9% and 47.6%, respectively, whereas hepatic IR/CR in 54.9% and 33.3%, respectively. The predictors of gastrointestinal CR were lower peak GvHD and steroid-dependent (SD) GvHD. The predictors for hepatic CR were male patient, reduced intensity conditioning and SD GvHD. Twenty-six of the 120 patients (21.6%) are currently alive (median follow-up for the survivors 91.5 months). The 12 months' overall survival is 30% with no treatment-associated deaths. Predictors of 12 months' survival were as follows: first transplant, age o 20 years, non-TBI regimen and GvHD CR. Shorter time to gastrointestinal IR but not time to hepatic IR was associated with improved 12 months' survival. IAS appears to be safe and effective. Gastrointestinal treatment is more effective than hepatic treatment. In our study, we conclude our current recommendations for IAS treatment.
INTRODUCTION
GvHD is the most severe side effect of allogeneic stem-cell transplantation. GvHD causes a severe inflammatory process, which may affect the skin and gastrointestinal system including the liver. The backbone of GvHD prevention and treatment are immunosuppressive agents including steroids, cyclosporine, tacrolimus, methotrexate (MTX) and anti-lymphocyte agents. All these agents aggravate immune incompetence, predisposing the patient to infections and secondary malignancies, as well as decreasing the efficacy of GvL effect. Furthermore, many immunosuppressive agents may defer the development of graft toward host tolerance. This could in turn inhibit or slow the resolution of GvHD.
In spite of the extensive systemic immunosuppressant use, o50% of the patients achieve control of GvHD. In others, GvHD may rapidly deteriorate and result in death. 1 Moreover, the prognosis of steroid-resistant (SR) or -dependent (SD) GvHD is usually poor, regardless of the choice of systemic immunosuppressant therapy used. 2, 3 Our group 4 and others 5, 6 have shown that an infusion of steroids directly into the artery supplying a GvHD affected organ (liver and/or gut) is safe and can induce remission of the GvHD. This 'locoregional' technique is aimed to deliver a larger dose of drug to the target organ by first-pass exposure, with lower systemic levels and toxicity.
Herein we report our cumulative experience in 120 consecutive patients with SR or SD liver and/or gastrointestinal GvHD, who received one of two IA treatment protocols. Predictors of response and survival are identified. To our knowledge, this is the largest cohort reported to date.
PATIENTS AND METHODS Patients
Consecutive patients who developed SR or SD acute or late acute GvHD (aGvHD), who were treated with adjuvant intra-arterial infusion of steroids (IAS) were included in this analysis. Between July 2000 and May 2015, 120 patients underwent IAS (Table 1) . Initially, IAS treatment was administered within study protocol (registered at ClinicalTrials.gov NCT00146978) with permission of the local institutional review board. Later, IAS treatment was incorporated into our standard GvHD treatment protocol. Before treatment, all patients or their legal guardians gave written informed consent. There were 68 males and 52 females, and median age of 34 years (range 3-70). The indications for transplant were acute leukemia, lymphoma or other various conditions in 96, 11 and 14 patients, respectively. Myeloablative and reduced intensity conditioning regimens were used in 85 and 35 patients, respectively, and TBI was part of the conditioning regimen in 28 patients. Twenty-four patients had undergone SCT (autologous or allogeneic) before the allogeneic stem-cell transplantation with which the GvHD episode was associated. Eighty-two patients received a graft from an HLA-matched donor (related or unrelated), whereas 33 patients received transplant from a mismatched donor. Six patients underwent haploidentical SCT from a related donor.
Treatment eligibility
Patients were eligible for inclusion if they developed gastrointestinal and/or hepatic stage 2-4 aGvHD or late aGvHD, which was either SR or SD. GvHD diagnosis was based upon clinical criteria and in most patients supported by biopsy. GvHD was staged according to the International Bone Marrow Transplant Registry severity index. 7 An infectious cause for the GvHD-related symptoms was excluded in all patients. GvHD may affect several organs simultaneously. However, not all organs are affected equally. For example, patients with SR gastrointestinal GvHD may have hepatic GvHD that does not fulfill the criteria of SR. These patients were termed gastrointestinal dominant and vice versa.
Steroid resistance was defined as one of the following: progression after 3 days, lack of response to at least 7 days or incomplete response to 14 days of standard treatment. Steroid dependence was defined as a GvHD response, which relapsed with decrease of the steroid dose. Standard treatment for aGvHD was IV methylprednisolone (MP) 2 mg/kg/day with or without other immunosuppressive agents such as cyclosporine, tacrolimus. After the IAS treatment, the anti GvHD regimen was continued in accordance with our institutional protocol. Unresponsive patients were permitted to receive further lines of anti-GvHD therapy.
Patients were excluded from IA treatment if they had advanced renal failure, paralytic ileus or uncontrolled multi-organ failure. Thrombocytopenia per se was not an exclusion criterion and patients were excluded only if they had uncontrolled bleeding tendency (other than gastrointestinal GvHD-associated bleeding).
Technique
The platelet count and INR were corrected whenever possible to 40 × 10 9 /L and o1.5, respectively, with a corrected hematocrit of at least 25%. If no increment was observed following transfusion, then the procedure was performed during infusion of platelets.
Using a standard common femoral artery approach and four or five French catheter and vascular sheath (depending on operator preference), visceral arteriography was performed using either a Cobra 2, Visceral or Rim catheter (Cook, Bloomington, IN, USA) with as little non-ionic contrast media as possible (Iomeron 300, Milan, Italy). Approximately 30-50 mL of contrast media was required per procedure. For treatment of gastrointestinal GvHD, the superior mesenteric artery (SMA), inferior mesenteric artery and internal iliac arteries were injected with MP, using the technique described below. The gastroduodenal artery was also treated in cases where significant GvHD of the upper gastrointestinal tract was encountered. Similarly, for hepatic GvHD the proper hepatic artery was catheterized and MP was infused. In the presence of variant hepatic arterial anatomy, the right and left hepatic arteries were selected using a microcatheter and~2/3 of the MP dose administered to the right lobe of the liver with the left lobe receiving the remainder. If the right hepatic artery was replaced from the SMA then the catheter tip was positioned beyond this vessel origin for treatment of the SMA territory.
The catheter tip was placed in the origin of each of the above target vessels for steroid infusion and MP dissolved in 20 ml normal saline was infused slowly over 3-5 min into each vessel. After completion of the MP infusion, the catheter and sheath were removed. Hemostasis was obtained using manual compression or, more recently, vascular closure devices (either Starclose, Abbott Vascular, Galway, Ireland, or Exoseal, Cordis, Johnson & Johnson, Cashel, Ireland) based on operator preference. Patients were kept on bed rest with restriction of limb flexion for between 2 and 6 h depending on the usage of closure devices.
Repeat IAS was performed according to patient response. Patients who had either no response or complete response (CR) to IAS did not have further treatments.
Intra-arterial treatment protocols. Initial protocol. As previously published, 4 patients with hepatic GvHD were treated with slow hepatic artery infusion of MP 75 mg/m 2 (max 125 mg) and MTX 10 mg/m 2 over 3-5 min. Patients with gastrointestinal GvHD were treated with IA infusion of MP 25 mg/m 2 (max 60 mg)/vessel into the SMA and inferior mesenteric artery. In patients with pronounced upper gastrointestinal symptoms suggestive of involvement of the stomach or duodenum, 25 mg/m 2 (max 40 mg) MP were also infused into the gastroduodenal artery.
Modified protocol. The original IAS protocol was modified in response to the outcome and side effects observed after implementation of the initial IAS protocol as follows: patients with hepatic GvHD were treated solely with slow hepatic arterial infusion of MP 600 mg/m 2 (with a maximal total dose of 1000 mg), whereas MTX was omitted. Patients with gastrointestinal GvHD were treated with IA infusion of 300 mg/m 2 (max 500 mg) MP into the SMA, 175 mg/m 2 (max 300 mg) to the inferior mesenteric artery and 60 mg/m 2 (max 100 mg) to each internal iliac artery. In patients with pronounced upper gastrointestinal symptoms, 60 mg/m 2 (max 100 mg) Abbreviations: AL = acute leukemia; GI = gastrointestinal; IAS = intra-arterial steroid; MM = mismatched; MAC = myeloablative conditioning; RIC = reduced intensity conditioning; SCT = stem cell transplant; SD = steroid dependent; SR = steroid resistant. Abbreviations: GDA = gastro-duodenal artery; GI = gastrointestinal; IAS = intra-arterial steroid; IIA = internal iliac arteries; IMA = inferior mesenteric artery; MP = methylprednisolone; MTX = methotrexate; SMA = superior mesenteric artery. GDA treatment was given only with upper GI symptoms.
MP was infused into the gastroduodenal artery. As we observed that some of the patients remained with rectal GvHD symptoms, we added 100 mg of MP to each internal iliac artery or more selectively to the anterior division of this vessel (Table 2 ).
Response criteria
Time to response was defined as the period from the day of IAS treatment to the day of observed clinical improvement in each involved organ according to the following criteria:
Hepatic. A decrease in serum bilirubin level by 25% of basal levels was termed 'initial response' (IR); reaching normal bilirubin levels was termed CR.
Gastrointestinal tract. Subjective amelioration of diarrhea with reduction in volume, frequency and abdominal pain, or the disappearance of bleeding was termed IR. The resolution of diarrhea and all other GI symptoms was termed CR. All possible adverse reactions that could be attributed to the IAS treatment were monitored and reported. Peripheral blood PCR for CMV and EBV were followed up to 6 months from the IAS procedure.
Statistical analysis
Overall survival (OS) was defined as death from any cause and surviving patients were censored at last contact. Non-relapse mortality (NRM) was defined as death without preceding evidence of progression/relapse; relapse was considered a competing risk. Relapse/progression was defined as progressive basic disease after allogeneic stem-cell transplantation or recurrence after a CR; NRM was considered a competing risk. The OS and response estimations were made according to the Kaplan-Meier method. Univariate analysis of prognostic factors was made with multiple and logistic regression. Statistical analyses were conducted at a 0.05 two-sided significance, unless otherwise stated.
The following variables were included in our analysis: (1) 
RESULTS
Classic aGvHD was observed in 92 patients, whereas 28 patients developed late aGvHD after immune suppression withdrawal or donor lymphocyte infusion (for prevention or treatment of disease relapse). Onset of aGvHD occurred at a median of 24 days, range (8-204) after transplant or post donor lymphocyte infusion.
Of a total 122 aGvHD episodes, 32 episodes were combined hepatic and gastrointestinal disease, 71 were gastrointestinal dominant and 19 were hepatic dominant. In total, 164 IAS procedures were performed (range 1-5 per patient).
Primary refractoriness to steroids was the reason for IAS treatment in 91 episodes, whereas in 31 episodes it was administered because of aGvHD flare up during steroid tapering. The median time from aGvHD to IAS was 20.5 days (5-528). Fifty-seven (47.5%) patients were treated with the initial protocol and 63 (52.5%) with the modified. Response to IAS in the whole cohort Gastrointestinal IR and CR were documented in 70\103 and 49\103 episodes, respectively, whereas hepatic IR and CR were seen in 28\51 and 17\51 episodes, respectively.
Response to IAS per treated organs. Hepatic aGvHD. Eleven out of 19 episodes with isolated hepatic treatment had IR to IAS in a median of 17 days (1-160) for a cumulative incidence of IR 57.9%. Nine out of the 19 episodes achieved CR following IAS in a median of 49 days, range (35-300). The cumulative incidence of CR to IAS was 47.4% ( Figure 1 ).
Gastrointestinal aGvHD. Fifty-four out of 71 episodes with isolated gastrointestinal treatment had IR in a median of 5 days (1-83) for a cumulative IR of 76.1%. Forty-two out of 71 episodes with isolated gastrointestinal involvement achieved CR in a median of 22 days, range (4-209). The cumulative incidence of CR to IAS was 59.2% ( Figure 1 ).
Combined hepatic and gastrointestinal aGvHD. Sixteen out of 32 episodes with combined hepatic and gastrointestinal infusion had hepatic IR in a median of 7.5 days (2-60) for a cumulative incidence of response of 50%. Eight of these episodes (25%) achieved hepatic CR in a median of 36.5 days (5-155 days). Sixteen of 32 episodes with combined infusion had gastrointestinal IR in a median of 5 days (1-41) for a cumulative incidence of IR of (50%).
Eleven of the 32 episodes (34.4%) achieved gastrointestinal CR in a median of 15 days, range (3-56). The cumulative incidence of hepatic and gastrointestinal CR to combined IAS was 7/32 (21.9%).
In comparison with treatment of an isolated organ vs combined organ treatments, there was a trend for better gastrointestinal CR in the isolated treatments ( Figure 1 , P = 0.059). There was no significant difference in the hepatic response rates.
Logistic regression: prediction of the response to IAS The predictors of gastrointestinal CR were lower peak GvHD (P = 0.01) and SD (rather than resistant) GvHD (P = 0.012). The predictors for hepatic CR-male patient (P = 0.006), reduced intensity conditioning (P = 0.02) and SD GvHD (P = 0.04). The protocol type had no effect on the proportion of the response, but the time for gastrointestinal CR (but not hepatic CR) was shorter with the modified protocol (30 and 13 days; P = 0.02).
Survival Twenty-six of the 120 patients (21.6%) are alive at the time of this report with a median follow-up on survivors of 91.5 months (25.7-197.4). Five were treated to the hepatic (26.3%), 14 (19.7%) to the gastrointestinal and 7 (21.9%) for both. The 12 months' OS is 30% (Figure 2 ). The cause of death was as expected, mainly NRM in 68 patients and relapse in 26, and was not statistically different between the protocols (Figure 3 ). There were no treatmentassociated deaths. Four IAS refractory patients were salvaged and survived.
Logistic regression for the prediction of survival Predictors of 12 months survival were as follows: having had a first transplant (P = 0.026), age below 20 years (P = 0.023), not having TBI as part of the conditioning regimen (P = 0.047), and gastrointestinal and hepatic GvHD CR to IAS (40.0001). Again, shorter time to gastrointestinal IR (P = 0.05) but not time to hepatic IR was associated with improved 12 months survival. The protocol type had no effect on survival.
Adverse events Major procedural complications included arterial hemorrhage, dissection or thrombosis (2/164), arterial spasm (2/164), renal failure (1/164, associated with MTX toxicity), groin hematoma (7/164) and cellulitis (1/164). Thirty-eight patients (31.7%) had CMV reactivation and 14 had CMV disease (11.7%; 11 gut, 3 pulmonary; without correlation to the protocol). Seventeen (14.1%) had EBV reactivation (significantly more common with the modified protocol (4 vs 13; P = 0.03)) and 3 (2.5%) had EBVassociated (Table 3 ). The patient with arterial hemorrhage underwent a successful urgent angiography and the bleeding was controlled. Other complications were managed conservatively. As mentioned above, there was no treatmentassociated mortality. DISCUSSION aGvHD remains the major contributor to early NRM in patients after allogeneic stem-cell transplantation. Despite years of research, the outcome of patients with severe GvHD remains dismal. The cornerstone of first-line treatment for aGvHD is corticosteroids. 8 Approximately 50% of patients treated for aGvHD achieve CR and OS at 6 months range from 48 to 89% in various studies. 9 In an effort to improve response rates, many other agents have been tested in combination with steroids as initial therapy, but none have convincingly shown a clear survival benefit. [10] [11] [12] Patients with SR GvHD have an even worse prognosis, with mortality rates in excess of 90% in the past. 13 Current therapies for refractory aGvHD may include anti-thymocyte globulin 14 and other antibodies, [15] [16] [17] [18] medications such as mycophenolate mofetil 19 or sirolimus 20 and procedures such as extracorporeal photochemotherapy 21 or mesenchymal cell therapy. 22 Unfortunately, despite the large number of recently introduced immunosuppressive agents there has been no change in the outcome of these patients 23 and results from relatively large trials (more than 40 patients enrolled) showed that CR rate tends tõ 30%. Out of the context of clinical trials, the CR rates to ATG (which remains the most widely used second-line agent) arẽ 20%. Administration of secondary treatment is also associated with worsening of immunosuppression, which is correlated with increased mortality due to infections and increased relapse rates. 24 The rationale behind IAS is the hypothesis that the intra-arterial infusion of steroids to the target organ would result in significant enhancement of the local effect of steroids with little or no increase of the systemic immunosuppression. Although not evaluated in pre-clinical studies using animal models, this strategy has been in clinical use for the treatment of solid tumors in various organs, including the liver, [25] [26] [27] based on increased first-pass exposure of the tumor. The beneficial effect of glucocorticoids is mediated through their anti-inflammatory and immunosuppressive properties. Glucocorticoids enter the cell cytoplasm and bind to the glucocorticoid receptor a (GRa). The complex corticoidsglucocorticoid receptor a, acts as a transcription factor, migrates into the nucleus and promotes the transcription of a wide spectrum of genes encoding for pro-inflammatory cytokines, regulators of apoptosis. 28, 29 The exact mechanisms of steroid action are largely unknown. In general, the therapeutic effect of glucocorticoids is mediated through the following: (1) general immunosuppression and (2) local control of inflammation in target organs. In fact, Bouazzaoui et al., 30 using a mouse GvHD model showed that the therapeutic activity of glucocorticoids in the liver and gut is mostly related to control of local inflammation and much less to a general suppression of T-cell expansion. Their experiment showed that prednisolone produces significant reduction of local expression in target organs of: (1) pro-inflammatory cytokines and chemokines such as interferon-γ and tumour necrosis factor, as well as (2) adhesion molecules such as LFA-1and others. Gut Peyer's patches and other secondary lymphoid organs were shown to be essential sites in initiating and maintaining aGvHD. 31, 32 We speculate that the high first-pass effect of MP, including lympholysis and change in the lymphocytes subsets, modulates these organelles and contributes to the beneficial effect of IAS.
In this study, we report mature long-term results of consecutive, non-selected patients treated with IAS. Initial and complete gastrointestinal response was documented in 67.9% and 47.6% episodes, respectively, whereas initial and complete hepatic response was documented in 54.9% and 33.3% episodes, respectively. In comparison of treatment to isolated organ vs combined organ treatments, there was a trend for better gastrointestinal response in the isolated treatments (59.2% vs 34.4% CR; P = 0.059) and there was no statistical significance in the hepatic responses (47.4% vs 25% CR; P = 0.3). Following our previous report on IAS, 4 other groups have used IAS for intestinal GvHD, [33] [34] [35] all with similar overall response ranging between 36 and 83%, and 33 and 63% CR, but it's use has not been otherwise reported for hepatic GvHD. Interestingly, the intra-arterial approach was used for the treatment of gastrointestinal GvHD with mesenchymal cells 36 and with platelets for gastrointestinal GvHD-associated bleeding. 37 Previous studies using ATG showed that the effectiveness of ATG is most pronounced in patients with skin GvHD, whereas efficacy is limited in cases with intestinal and/or liver involvement. In our study, which consisted exclusively of patients with hepatic and/or intestinal disease, the observation of up to 59% gastrointestinal CR rate and 47% hepatic CR seems favorable.
As this is the largest cohort yet reported, we analyzed the probabilities of response and survival with IAS. The predictors of gastrointestinal CR were lower peak GvHD and SD GvHD, whereas for hepatic CR the predictors were male patient, reduced intensity conditioning and SD GvHD. The protocol type had no effect on response.
As to 12 months' survival, other than the obvious that sicker patients (not having the first transplant, age above 20 years) do worse, we have seen that there is association between the response to IAS and 12 months' survival. We also report that shorter time to gastrointestinal IR but not hepatic IR is associated with better 12 months' survival. This is reasonable, as gastrointestinal GvHD causes loss of intestinal barrier with common translocation of luminal bacteria, thus the faster the barrier is restored, the better the expected outcome. This is not the case with hepatic GvHD, and slow responding patients can tolerate a longer time to response.
Recently, Socie et al. 38 reported a randomized study of ATG vs Inolimomab in SR GvHD with 47% OS at 1 year. However, their report contained significant selection bias due to inclusion of many patients with skin GVHD, while excluding patients with active disease at transplant, those having haplo transplant, with poor performance status or with major liver functional test abnormalities. Interestingly, a Spanish group using Inolimomab reported 2-year OS of 18% for their entire cohort and 33% for the day 30 responders. 39 In our study, including patients treated since 2000, the OS was 30% at 12 months. However, if patients who died from relapse are excluded from analysis, the OS improves to 43.3%. We hope that with advancement of supportive care, we will be able to reduce the NRM, take advantage of the response rate and further improve the OS.
ATG and monoclonal antibodies cause severe and long-lasting depression of immunity resulting in the emergence of opportunistic infections. On the contrary, the efficacy of IAS is mainly based on the local control of inflammation and therefore is associated with decreased of the severe and global immune-suppression effect provoked by other immunosuppressive regimens. Our patients experienced less CMV reactivation and disease as compared with the reports in the literature describing the side effects of systemic immune suppression for refractory GvHD (31.7% and 11.7% vs 48-58.3% and 17.9-22%). 18, 22, 39, 40 Interestingly, EBV reactivation was significantly more common with the modified protocol (with higher dose of MP). Potential immediate complications directly attributed to IAS are those associated with arterial catheterization. These may include arterial rupture, dissection or thrombosis, temporary arterial spasm, groin hematoma or cellulitis and rarely renal failure. In our center, IAS is performed by experienced angiographers; thus, major complications from the procedure were infrequent. Platelets were routinely administered in thrombocytopenic patients and, other than one patient with arterial rupture, no episodes of major hemorrhage during or following catheterization were observed. Patients were well hydrated before the procedure and intravascular contrast doses were kept to a minimum.
There are several limitations to this report including the fact that it is non-randomized, non-blinded, performed at a single center, and that patients were allowed other concomitant anti-GvHD treatment (ethically mandatory).
In conclusion, the results of this study suggest that adjuvant IAS appears to be safe and effective. We are able to report on factors that may be predictive of response and survival. It is hoped that other centers will include this approach in their standard care algorithm. Our experience is that all those who consulted us in the past, 33, 34 are using this method. As is no difference between the original and the modified protocol, and with interest of exempting the use of MTX, our current recommendations for IAS are listed in Table 4 . If a center is hesitant about using IAS alone, there is rationale to combine local and systemic effects by giving IAS in conjunction with systemic second-line treatment. We feel that every effort should be made to perform a prospective randomized study with large numbers of patients to evaluate optimal dosage, time, method and frequency of administration. Endpoints in these studies may include day 28 and/or day 42 response rate and the timing of withdrawal of all immunosuppression and cost-effectiveness analysis.
